Only actual and fresh news

Merck's human papillomavirus vaccine, Gardasil, effectively prevented precancerous cervical lesions and genital warts in women ages 24 through 45, and it prevented anal cancer and precancerous anal lesions in young men who have sex with men, according to two studies released by the company on Wednesday, the AP/Philadelphia Inquirer reports...

A new paper to be published in BJOG: An International Journal of Obstetrics and Gynaecology outlines a number of ongoing questions and challenges related to HPV vaccination. These include the decision to limit vaccination to adolescent girls, and the importance of continued screening...

The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices on Wednesday recommended GlaxoSmithKline's human papillomavirus vaccine, Cervarix, for routine use in vaccinating girls and young women to prevent cervical cancer, the AP/New York Times reports (Stobbe, AP/New York Times, 10/21).

The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices on Wednesday is scheduled to consider whether to recommend vaccination of boys with Merck's human papillomavirus vaccine Gardasil, NPR's "All Things Considered" reports.

FDA on Friday approved GlaxoSmithKline's human papillomavirus vaccine Cervarix for use in girls and women ages 10 through 25 to prevent cervical cancer, and it

A recent study in the British Medical Journal finding that it would not be cost effective to vaccinate boys and men against the human papillomavirus unfairly shifts the responsibility for vaccination to girls and women, Slate columnist William Saletan writes.

Vaccinating boys and men with Merck's Gardasil to protect against genital warts does not appear to be cost effective if all girls and women receive the vaccine to prevent genital warts and human papillomavirus, according to a study in the British Medical Journal,

An FDA panel on Wednesday recommended that the agency approve GlaxoSmithKline's human papillomavirus vaccine, Cervarix, to prevent cervical cancer, as well as expand approval of Merck's HPV vaccine, Gardasil, to include use in men ages nine to 26 for the prevention of genital warts, the Wall Street Journal reports.

Merck & Co., Inc. announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee agreed that efficacy, immunogenicity and safety data from clinical trials in males support the use of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] in boys and men 9 through 26 years of age for the prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11.

An FDA Advisory Committee meeting scheduled for this Wednesday will address GlaxoSmithKline's application for approval of its human papillomavirus vaccine, Cervarix, as well as Merck's vaccine Gardasil for use in males to prevent genital warts, the

Informing men that a new vaccine to prevent human papillomavirus (HPV) would also help protect their female partners against developing cervical cancer from the sexually transmitted infection did not increase their interest in getting the vaccine, according to a new Florida State University study.